Search Results - "Clemons, Mark J."

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer by BROOM, Reuben J, TANG, Patricia A, SUMMONS, Christine, BORDELEAU, Louise, MULLIGAN, Anna Marie, O'MALLEY, Frances P, MILLER, Naomi, ANDRULIS, Irene L, BRENNER, Darren M, LEMONS, Mark J

    Published in Anticancer research (01-05-2009)
    “…Background: Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines by Fralick, Michael, Ray, Monali, Fung, Christina, Booth, Christopher M., Mallick, Ranjeeta, Clemons, Mark J.

    Published in The oncologist (Dayton, Ohio) (01-11-2013)
    “…Learning Objectives Summarize findings regarding the media's portrayal of bevacizumab with each phase of therapeutic development. Identify media sources of…”
    Get full text
    Journal Article
  13. 13

    Lost in Transition? Thoughts on Retirement—“Will You Still Need Me, Will You Still Feed Me, When I'm Sixty‐Four?” by Clemons, Mark J., Vandermeer, Lisa A., Gunstone, Ian, Jacobs, Carmel, Kaizer, Leonard, Paterson, Alexander H.

    Published in The oncologist (Dayton, Ohio) (2013)
    “…Oncologists should plan for a future beyond full‐time oncology, but there is little practical guidance for a successful transition into retirement. This paper…”
    Get full text
    Journal Article
  14. 14

    Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction? by Freedman, Orit C, Amir, Eitan, Clemons, Mark J

    Published in Critical reviews in oncology/hematology (01-10-2009)
    “…Abstract Bone is the most common site of metastatic spread in breast cancer patients. The use of bisphosphonates (BPs) in women with bone metastases from…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Delivery of cancer care via an outpatient telephone support line: A cross-sectional study of oncology nursing perspectives on quality and challenges by Shah, Hely, Vandermeer, Lisa, MacDonald, Fiona, Laroque, Gail, Nelson, Shannon, Clemons, Mark J., McGee, Sharon

    Published in Journal of clinical oncology (01-10-2022)
    “…427 Background: Patient support lines (PSLs) help in triaging clinical problems, addressing patient queries and assist in navigating a complex…”
    Get full text
    Journal Article
  17. 17

    Can synthetic data accurately mimic oncology clinical trials? by El Kababji, Samer, Mitsakakis, Nicholas, Fang, Xi, Beltran-Bless, Ana-Alicia, Pond, Gregory Russell, Vandermeer, Lisa, Radhakrishnan, Dhenuka, Mosquera, Lucy, Clemons, Mark J., El Emam, Khaled

    Published in Journal of clinical oncology (01-06-2023)
    “…1554 Background: There is strong interest by researchers, the pharmaceutical industry, medical journal editors, funders of research, and regulators in sharing…”
    Get full text
    Journal Article
  18. 18

    Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach by Cole, Katherine, McGee, Sharon, Clemons, Mark J., Liu, Michelle, MacDonald, Fiona, Vandermeer, Lisa, Ng, Terry L., Pond, Gregory Russell, El Emam, Khaled

    Published in Journal of clinical oncology (01-06-2023)
    “…e24126 Background: Vasomotor symptoms (VMS), such as hot flashes, are a common reason for early discontinuation of endocrine therapy for patients (pts) with…”
    Get full text
    Journal Article
  19. 19

    The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials by Kushnir, Igal, Clemons, Mark J., Fergusson, Dean, Bosse, Dominick, Reaume, M. Neil

    Published in Journal of clinical oncology (20-05-2020)
    “…Abstract only e14099 Background: Randomized trials are considered the gold standard when assessing the efficacy of new therapeutic agents. In settings where…”
    Get full text
    Journal Article
  20. 20

    Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? by Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., Clemons, M.J.

    Published in Annals of oncology (01-09-2009)
    “…Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and Her2…”
    Get full text
    Journal Article